Mineralys Therapeutics, Inc. (MLYS)
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$154.7M
- Total assets
- $661.8M
- Market cap
- $2.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $170.6M
- Operating income
- -$170.6M
- Income tax
- $0
- Net income
- -$154.7M
- EPS (basic)
- $-2.29
- EPS (diluted)
- $-2.29
Balance sheet
- Total assets
- $661.8M
- Current assets
- $661.4M
- Total liabilities
- $15.1M
- Current liabilities
- $15.1M
- Shareholders’ equity
- $646.7M
Cash flow
- Operating cash flow
- -$142.4M
- Investing cash flow
- -$389.8M
- Financing cash flow
- $591.0M
- Net cash flow
- $58.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.1B
- EPS (diluted)
- $-2.29
- Shares outstanding
- 78.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 2023
Mineralys Therapeutics, Inc. (MLYS) Stock Price
- Reported a net loss of $154.7M.
- Trading 44% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Mineralys Therapeutics, Inc..
Write a review
News about Mineralys Therapeutics, Inc.
News & sentiment via Polygon.io
Mineralys Therapeutics, Inc.: frequently asked questions
Is Mineralys Therapeutics, Inc. an American company?
Mineralys Therapeutics, Inc. is a US-based company headquartered in Radnor, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Mineralys Therapeutics, Inc. headquartered?
Mineralys Therapeutics, Inc. is headquartered in Radnor, Pennsylvania, United States.
Is Mineralys Therapeutics, Inc. publicly traded?
Yes — Mineralys Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol MLYS on the NASDAQ.
What does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
